Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.
Ingrid Espinoza, Chandra Kurapaty, Cheol-Hong Park, Travis Vander Steen, Celina G. Kleer, Elizabeth L. Wiley, Alfred Rademaker, Elisabet Cuyàs, Sara Verdura, María Buxó, Carol Reynolds, Javier A. Menéndez, Ruth Lupu
Abstract
notably reduced tumor burden, which was accompanied by decreased microvessel density and concurrent induction of the luminal epithelial marker E-cadherin. Thus, CNN1/CYR61-targeting strategies might have therapeutic value in suppressing the biological aggressiveness of triple-negative/basal-like BC.
Topics & Concepts
CYR61Triple-negative breast cancerMatricellular proteinCancer researchGene silencingBasal (medicine)Breast cancerBiologyCancerTissue microarrayPathologyImmunohistochemistryMedicineReceptorImmunologyEndocrinologyCell biologyCTGFExtracellular matrixGrowth factorGeneGeneticsBiochemistryInsulinConnective Tissue Growth Factor ResearchBiomarkers in Disease Mechanisms